根据Wind数据统计，截至8月21日，社保基金持有129只股票，持股市值合计达332亿元。在个股选择上，持有市值前 十的个股为银行板块的常熟银行、PCB板块的鹏鼎控股、农业板块的海大以及化工龙头万华化学。 序号 从行业板块看，集中在化工、硬件设备、食品饮料、医药生物和银行。其中低位板块化工板块持股市值达60亿位列第 一。 名称 持股数量(万股)-本期 持股市值(万元)-本期 Wind行业 1常熟银行27779.13 204732.18 银行2鹏鼎控股4301.00 137760.98 硬件设备3海大集团2103.44 123240.26 食品饮料4万华 化学2120.99 115084.84 化工5信维通信3700.00 82880.00 硬件设备6藏格矿业1812.00 77318.04 化工7涪陵电力8169.94 75163.43 公用事业Ⅱ8华东医药1758.97 70992.21 医疗设备与服务9思源电气935.74 68224.45 电气设备10华工科技 1437.52 67577.86 硬件设备 近期化工板块再起攻势。成份股方面，今日钛白粉、氮肥、钾肥、聚氨酯等板块部分个股涨幅居前，中核钛白涨停 ...

Financial Data and Key Metrics Changes - In Q2 2025, revenue decreased by approximately 6% to $3.8 million compared to $4.1 million in 2024, reflecting additional expenses related to the transition and integration of the Sleep Center of Nevada (SCN) [8][10] - Operating loss widened to $4.9 million in Q2 and $8.8 million for 2025, primarily due to higher expenses and lower revenues during the strategic transition [11][12] - Cash and cash equivalents stood at $4.4 million with total liabilities of $21.5 million as of June 30, 2025 [12] Business Line Data and Key Metrics Changes - VIP enrollment revenue declined by $1 million in Q2, while sleep testing service revenue saw an uplift of $500,000 attributable to SCN [9][10] - Oral appliance sales decreased by 5% in Q2, with 4,116 units sold for $1.9 million, reflecting a shift towards higher volume guide sales [10][11] Market Data and Key Metrics Changes - The integration of SCN has led to increased patient demand, with the company currently servicing significantly less than 40% of potential new patients being tested each month at SCN [18][19] - The company has identified a significant number of legacy SCN patients dissatisfied with CPAP units, indicating a strong market opportunity for VIVOS's treatment alternatives [18] Company Strategy and Development Direction - The company is focusing on a new sales, marketing, and distribution model centered around sleep center provider alliances and acquisitions, with the SCN acquisition being a key milestone [6][12] - VIVOS plans to expand its operations by deploying additional Sleep Optimization (SO) teams to meet growing patient demand, with potential for up to eight teams at SCN based on current demand [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the integration of SCN and the initial patient demand exceeding expectations, leading to plans for facility expansion and additional staff recruitment [14][18] - The company anticipates becoming cash flow positive by the fourth quarter of 2025 as it ramps up the deployment of SO teams [49] Other Important Information - The company has secured significant debt and equity financing, providing $11.5 million in net cash from financing activities [11][12] - VIVOS is actively pursuing additional acquisition and affiliation opportunities across the country, with ongoing negotiations with several potential candidates [22][39] Q&A Session Summary Question: How should revenue in Q3 and Q4 be viewed relative to Q2? - Management indicated that revenue will track the deployment of SO teams, with expectations for growth as the new model replaces the old one [26][27] Question: Will the strength in sleep testing services continue? - Management noted that the increase in testing revenue is a direct reflection of SCN's operations and expects continued growth as more testing centers are brought online [28][29] Question: What is the expected operating expense moving forward? - Management acknowledged that there were one-time costs associated with the SCN acquisition, but some ongoing costs will remain [31][32] Question: How is the recruitment of SO teams progressing? - Management reported robust demand for positions and efficient training processes for new teams [35][36] Question: What is the financial strategy regarding debt? - Management is focused on reducing the cost of capital and is exploring opportunities for refinancing as the business model matures [44][45] Question: When does management expect to reach cash breakeven? - Management is targeting cash flow positivity by the fourth quarter of 2025 as they expand operations [49]

Group 1 - The China Securities Index for healthcare equipment and services has shown a positive trend, with notable stock increases such as 20.01% for Toujing Life and 20.00% for Furuijian [1] - The Ministry of Industry and Information Technology, along with six other departments, has issued implementation opinions to promote the innovation and development of the brain-computer interface industry, aiming for breakthroughs in key technologies by 2027 [1] - The brain-computer interface technology is experiencing rapid changes, with expectations for significant market expansion as domestic companies move towards commercial applications [1] Group 2 - Recent performance forecasts in the medical consumables sector indicate that low-value consumables are affected by US-China tariff policies, while high-value consumables are gradually recovering from centralized procurement impacts [2] - The optimization of centralized procurement policies in the pharmaceutical sector is expected to restore market confidence in the entire consumables industry [2] - The China Construction Bank's ETF closely tracks the China Securities Index for healthcare equipment and services, reflecting the overall performance of listed companies in this sector [2]

Group 1 - The China Construction Bank Zhejiang Branch announced the winning candidate for the procurement project of the self-service payment system for radiology medical fees at Dongyang People's Hospital, which is Zhejiang Chengtao Engineering Co., Ltd [1] - The total amount of the winning bid by Shanghai Datu Medical Technology Co., Ltd is 295,000 [2] - China Construction Bank has invested in 842 enterprises and participated in 60,421 bidding projects, with a total of 2,436 trademark records, 13,032 patent records, and 1,101 copyright records [1]

Core Insights - Tandem Diabetes Care, Inc. (TNDM) reported a second-quarter 2025 loss of 48 cents per share, missing the Zacks Consensus Estimate of a loss of 40 cents per share, while GAAP loss was 78 cents per share compared to a loss of 47 cents in the prior year [1][9] - Following the earnings announcement, TNDM stock experienced a decline of 20% [1] Revenue Performance - Non-GAAP revenues for the quarter reached $240.7 million, reflecting an 8.5% year-over-year increase and surpassing the Zacks Consensus Estimate by 0.9% [2][9] - GAAP revenues also totaled $240.7 million, marking an 8.5% increase year over year [2] Geographic Sales Breakdown - In the United States, non-GAAP sales amounted to $170.2 million, a 9% increase year over year, with approximately 21,000 pumps shipped [4] - Outside the United States, non-GAAP sales were $70.5 million, up from $65.2 million in the prior-year period [5] Margin and Expense Analysis - Gross profit for the quarter was $125.9 million, an 11.6% increase year over year, with gross margin expanding by 146 basis points to 52.3% despite a 5.2% rise in cost of sales [6][9] - SG&A expenses rose by 16.3% to $109.6 million, while R&D expenses decreased by 2.4% to $48.1 million [6] Financial Position - At the end of the second quarter of 2025, Tandem Diabetes had cash, cash equivalents, and short-term investments totaling $315.4 million, down from $368.6 million at the end of the first quarter [7] Future Guidance - The company provided full-year 2025 GAAP financial guidance, estimating sales to be approximately $1.00 billion, with U.S. sales expected to be $700 million and international sales projected at $300 million [10] Product Developments - During the second quarter, Tandem initiated an early access program for the t:slim X2 insulin pump with Control-IQ+ technology and received CE Mark for the Tandem Mobi insulin delivery system with Control-IQ+ technology [12]

人民财讯8月11日电，合富中国（603122）8月11日晚间公告，公司2025年1—7月合并营业收入4.25亿 元，较去年同期下降22.66%，2025年1—6月合并营业收入较去年同期下降23.53%，下降幅度收窄 0.87%，营收情况持续改善。 ...

Financial Data and Key Metrics Changes - Year-over-year revenue increased by 14.7%, driven entirely by organic growth, keeping within the anticipated range for organic growth during the year [23] - Gross margin for the quarter was 58.3%, down from 59.8% in 2024 and 56.3% in 2025, reflecting a decline consistent with previous quarters [23][24] - Adjusted EBITDA grew 12% year-over-year to $14.3 million, with an adjusted EBITDA margin of 22.7% [24][30] Business Line Data and Key Metrics Changes - Ventilation business accounted for 54% of revenues, with vent revenue up 5% sequentially and 11% year-over-year [11][23] - Sleep therapy patients increased by 15% sequentially and 51% year-over-year, with new patient sales up 72% year-over-year [12][23] - Resupply program patients were up 10% sequentially and 25% year-over-year, indicating strong growth in this segment [13] - Staffing business experienced a sequential slowdown due to softened labor demand, although it was up year-over-year [14][20] Market Data and Key Metrics Changes - The sleep business now represents 19% of total revenues, reflecting its rapid growth and importance to the overall revenue mix [23][45] - The staffing business, which accounts for approximately 10% of total revenue, is primarily driven by behavioral and social service needs [20] Company Strategy and Development Direction - The company is focused on expanding its addressable at-home market, with the acquisition of Lehan Medical Equipment marking a strategic step into maternal health [8][10] - The company aims to diversify its patient base and leverage existing infrastructure to reach new patient populations [8][10] - The management emphasizes disciplined execution of long-term strategies, resulting in tangible growth across core and complementary services [6][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the evolving regulatory landscape, particularly with the new NCD final rule, which is expected to reduce operational burdens [15][18] - The company anticipates continued organic growth and has raised its full-year guidance for net revenue and adjusted EBITDA, reflecting optimism for the second half of the year [30][32] - Management noted that the industry is well-positioned to educate regulators and present solutions, enhancing the company's competitive stance [18][19] Other Important Information - The company has a strong balance sheet with $55 million available on credit facilities and $20 million in cash, enabling share repurchase programs and acquisitions [28][29] - The company completed a ventilator exchange program, which is expected to normalize CapEx going forward and improve adjusted free cash flow [26][30] Q&A Session Summary Question: Can you elaborate on the benefits of the BENT program upgrade and exchanges? - The financial benefits include cash back for the vents, generally higher than net book value, and the clinical value lies in acquiring newer, technologically advanced assets [35][36] Question: What is the administration's view on DME in general? - The administration is looking to cut costs across government sectors, and competitive bidding pressure is anticipated [39][40] Question: Were there any unusual factors contributing to the growth in sleep therapy patient count? - Growth is attributed to an expanded sales force and increased operational efficiency, with no significant negative impact from GLP-1s [44][45] Question: What drove the decline in service revenue in the staffing business in Q2? - The decline is linked to behavioral health and social service needs, with expectations for appropriations to improve in the back half of the year [48][49]

STERIS (STE) Q1 2026 Earnings Call August 07, 2025 09:00 AM ET Speaker0Good day, and welcome to the STERIS PLC first quarter twenty twenty six conference call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on a touch tone phone.To withdraw your question, please press star then 2. Pleas ...

Core Viewpoint - The healthcare equipment and services sector is experiencing a significant boost, driven by policy support for AI in healthcare, with notable stock price increases among key companies in the industry [1] Group 1: Market Performance - As of August 7, 2025, the CSI All Index for Healthcare Equipment and Services (H30178) rose over 2%, currently up by 1.00% [1] - Key stocks such as Diedeman (300289) increased by 20.02%, Sainuo Medical (688108) by 20.01%, and Zhonghong Medical (300981) by 19.99% [1] Group 2: Policy Support - The State Council's executive meeting approved the "Artificial Intelligence+" action plan on July 31, indicating strong and clear policy support for AI applications in healthcare [1] - The AI applications in healthcare, particularly in AI pathology diagnosis, AI imaging, and AI pharmaceuticals, are expected to accelerate their commercialization process [1] Group 3: Industry Initiatives - On August 1, the National Healthcare Security Administration held a press conference to introduce the "Inviting Talents to Assist Medical Innovation" 2025 National Smart Healthcare Competition, marking the official launch of the competition [1] - The CCB CSI All Index for Healthcare Equipment and Services ETF (159891) closely tracks the CSI All Index for Healthcare Equipment and Services, reflecting the overall performance of listed companies in the healthcare sector [1]

Core Insights - Steris reported Q1 FY2026 earnings, showing solid year-over-year growth but falling short of analyst expectations for both revenue and adjusted EPS [1][2] - Revenue (GAAP) was $1,391.1 million, below the estimate of $1,447.8 million, while adjusted EPS was $2.34 compared to the consensus estimate of $2.47 [1][2] - Increased tariffs and higher employee benefit costs offset foreign currency gains, leading to an unchanged adjusted earnings outlook despite a raised revenue forecast [1][9] Financial Performance - Non-GAAP EPS for Q1 FY26 was $2.34, a 15.3% increase from $2.03 in Q1 FY25 [2] - GAAP revenue increased by 8.7% year-over-year, from $1,279.5 million in Q1 FY25 to $1,391.1 million [2] - Free cash flow (non-GAAP) rose by 66.8% to $326.5 million compared to $195.7 million in Q1 FY25 [2] Segment Performance - The Healthcare segment generated $974.7 million in revenue, an 8.2% increase from $901.2 million in Q1 FY25 [2][5] - The Applied Sterilization Technologies (AST) segment saw a 12.6% revenue increase, driven by a 12% growth in services and a 46% increase in capital equipment sales [5] - Life Sciences revenue grew by 5.2%, supported by a 53.8% rise in backlog compared to Q1 FY25, indicating strong future demand [5] Operational Developments - Income from operations (GAAP) increased by 32.6% year-over-year, driven by higher pricing and operational productivity [6] - Cash flow from operations rose to $420.0 million, a 38% increase from $303.7 million in Q1 FY25 [6] - Inventory increased by $59.9 million, indicating investments for future growth [6] Strategic Focus - Steris is focusing on expanding its service business and managing global supply chain challenges [4] - The company emphasizes compliance with healthcare regulations and innovation in sterilization technologies [4] - Management raised the revenue growth forecast for FY2026 from 6-7% to 8-9%, driven by favorable foreign currency shifts [9] Cost Challenges - Tariff-related costs are projected to rise from $30 million to $45 million annually, impacting profitability [7] - Labor and employee healthcare costs continue to increase, affecting overall margins [7] - R&D expenses increased to $26.4 million, reflecting ongoing investment in future offerings [7]